Melanoma is a type of skin cancer that can spread elsewhere in the body
SCIENCE PHOTO LIBRARY
After decades of research and clinical trials, a new breakthrough in cancer treatment may soon be on the horizon. A genetically modified herpes virus, known as RP1, has shown promising results in treating advanced melanoma, a deadly form of skin cancer that can spread throughout the body.
In a study involving 140 patients with advanced melanoma, RP1 was injected directly into the tumors of individuals who had not responded to standard treatment. These patients also received nivolumab, a drug that enhances the immune system’s ability to target cancer cells.
The results were remarkable, with a 30% response rate observed in patients, leading to tumor shrinkage and even complete disappearance in some cases. Dr. Gino Kim In from the University of Southern California expressed optimism about the findings, stating that the efficacy of RP1 far surpasses existing treatment options for advanced melanoma.
Further trials involving 400 patients are currently underway, with the possibility of RP1 receiving approval from the FDA for treating advanced melanoma in conjunction with nivolumab. This could revolutionize the way melanoma is treated and offer new hope for patients facing this aggressive form of cancer.
The use of viruses to target cancer cells has been studied for over a century, but only recently have genetically modified viruses like RP1 shown significant promise in cancer treatment. These viruses work by infecting cancer cells and triggering an immune response to attack tumors throughout the body.
Compared to previous virus-based treatments like T-VEC, RP1 has shown superior efficacy in targeting deep-seated tumors and inducing a systemic immune response. If approved, RP1 could become a game-changer in cancer therapy and pave the way for more advanced viral treatments in the future.
